Business Wire

Simpson Thacher Expands Secondaries Team With Hire of Ed Ford and Sacha Gofton-Salmond

13.2.2023 19:00:00 EET | Business Wire | Press release

Share

Simpson Thacher & Bartlett LLP announced today that Ed Ford and Sacha Gofton-Salmond will join the Firm as Partners in the London office, where they will focus on secondaries transactions.

“Ed and Sacha are highly regarded in the secondaries space, having built up a market leading practice in recent years and will add depth to our renowned Private Funds and Fund Transactions Practices, further bolstering our ability to advise sponsors and investors on liquidity solutions that provide additional flexibility to address an ever-changing market,” said Alden Millard, Chair of Simpson Thacher’s Executive Committee. “We are thrilled to welcome them to Simpson Thacher.”

“Simpson Thacher has developed a robust presence in the fund transactional space, which was strengthened by the addition of Lauren King in New York in 2021,” said Michael Wolitzer, Head of Simpson Thacher’s Investment Funds Practice. “With the addition of Ed and Sacha, the Firm is further augmenting its capabilities to provide sponsor clients and other industry participants with multidisciplinary secondaries solutions around the globe.”

Ed and Sacha both specialize in advising clients on the structuring and negotiation of highly complex secondary market solutions, ranging from GP- and LP-led secondary transactions to NAV financings, preferred equity financings and other structured secondary transactions. Both lawyers join the Firm from Travers Smith.

“Ed and Sacha are both incredibly talented lawyers that have the versatile experience and commercial creativity that is the hallmark of Simpson Thacher’s Investment Funds Practice,” said Jason Glover, Head of Simpson Thacher’s London office and the Firm’s European Funds team. “We have admired Ed’s and Sacha’s respective success in the secondaries space for some time and believe that their arrival at Simpson Thacher will enhance our existing secondaries transaction platform in London. Such hires mark the latest step in enhancing our private funds offering and solidifying our position as the global investment funds law firm of choice.”

Simpson Thacher’s Fund Transactions Practice advises on the full breadth of secondaries transactions, as well as complex control and minority-stakes transactions involving alternative asset managers and preferred and structured financings for funds, their management companies and other industry participants. Drawing upon the Firm’s more than 40 years of experience in the private equity industry, the global team comprises funds, mergers and acquisitions, finance, tax and other lawyers who provide commercially-driven, comprehensive transactional advice for the world’s most sophisticated sponsors. The multidisciplinary team offers deep market knowledge and creative, tailored advice on transactions, including traditional and synthetic secondaries deals, GP-led restructurings, preferred equity transactions and other liquidity solutions.

ABOUT SIMPSON THACHER

Simpson Thacher & Bartlett LLP (www.simpsonthacher.com) is one of the world’s leading international law firms. The Firm was established in 1884 and has more than 1,000 lawyers. Headquartered in New York with offices in Beijing, Brussels, Hong Kong, Houston, London, Los Angeles, Palo Alto, São Paulo, Tokyo and Washington, D.C., the Firm provides coordinated legal advice and transactional capability to clients around the globe.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Arielle Katz
Communications Manager
mediainquiries@stblaw.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release

Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs

ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 19:26:00 EEST | Press release

ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, frustrated with outdated tools, or looking to connect with peers solving similar problems and putting AI to work. Renowned technology analyst and former Andreessen Horowitz

eM Client 11 Launches: A European Outlook Alternative Bringing AI Freedom, Digital Sovereignty, and Next-Generation Productivity14.10.2026 19:16:00 EEST | Press release

eM Client, the European developer of the popular email and productivity application used by millions worldwide, today announced the release of eM Client 11, its most significant update yet. The new version introduces advanced AI capabilities, and major productivity improvements, strengthening its position as an independent alternative to Microsoft Outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014945464/en/ eM Client 11 main window AI Without Vendor Lock-In eM Client 11 introduces a powerful AI Assistant that enables users to search, summarize, organize, and manage emails using natural language. Additional features include personalized AI writing, context-aware quick replies, automatic task and event detection, and AI-powered email rules. Unlike traditional AI integrations, eM Client 11 supports Bring Your Own Key (BYOK), allowing organizations to connect compatible AI providers and models of their choice. The re

iQmetrix and Stratus HR Partner to Give Wireless Retailers a Complete, Outsourced HR Department14.10.2026 18:15:00 EEST | Press release

Stratus HR, a full-service human resources outsourcing provider, today announced a partnership with iQmetrix, the Intelligent Commerce Operating System for telecom. As a Professional Employer Organization (PEO), Stratus HR becomes the complete, outsourced HR partner for wireless retailers on iQmetrix – payroll, benefits, compliance, and on-call HR experts – so retail teams stay focused on selling and serving customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014178512/en/ Fully integrated with iQmetrix, Stratus HR’s custom-built technology connects the employee lifecycle to the store: new hires, terminations, rehires, position moves, and security-role updates flow straight into the point of sale (POS), while hours flow from the retailer’s iQmetrix system into payroll – eliminating double entry and pay errors, so every paycheck is accurate and every new hire hits the floor faster. Frontline teams get enterprise-leve

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye